Form 4: Regeneron Director Zoghbi Acquires Stock & Options

Regeneron Pharmaceuticals Director Huda Y. Zoghbi reported the acquisition of 155 restricted stock units and 1,962 non-qualified stock options on January 2, 2026, as part of her compensation.

Summary

• Huda Y. Zoghbi, a Director of Regeneron Pharmaceuticals, Inc. (REGN), acquired securities on January 2, 2026.
• The acquisition included 155 shares of Common Stock in the form of time-based vesting restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, with an acquisition price of $0.0.
• Following this transaction, Zoghbi beneficially owns 1,703 shares of Common Stock directly.
• Additionally, 1,962 non-qualified stock options were acquired, with an exercise price of $772.76.
• These options have an expiration date of January 2, 2036.
• A portion of the stock options will become exercisable on the date of the Issuer's first annual meeting of shareholders following the grant date, with the remainder exercisable on the first anniversary of the grant date.
• Following this transaction, Zoghbi beneficially owns 1,962 derivative securities (options) directly.

Sentiment

Score: 7

Explanation: The filing indicates a routine grant of equity compensation to a director, which is generally viewed positively as it aligns the director's interests with shareholders. It does not contain any unexpected positive or negative news.

Positives

• Director Huda Y. Zoghbi increased her direct beneficial ownership in Regeneron Pharmaceuticals, Inc. by acquiring 155 restricted stock units and 1,962 non-qualified stock options.
• The acquisition of equity-based compensation aligns the director's interests with those of shareholders, potentially fostering greater commitment to company performance.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine equity compensation for a director, a common practice across the pharmaceutical and biotechnology industries to align executive and director incentives with long-term shareholder value. It does not provide broader industry trend insights.

Related Party Transactions

• The acquisition of restricted stock units and non-qualified stock options by Director Huda Y. Zoghbi represents a compensation-related transaction between a related party (director) and the issuer.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, potentially fostering greater commitment to company performance.

Next Steps

• A portion of the acquired stock options will become exercisable on the date of Regeneron's first annual meeting of shareholders following the grant date.
• The remainder of the stock options will become exercisable on the first anniversary of the grant date.
• The restricted stock units will vest based on time-based conditions.

Key Dates

Recommendation

This Form 4 filing details a routine grant of equity compensation to a director and does not contain information that would fundamentally alter the investment thesis for Regeneron Pharmaceuticals. While insider acquisitions of equity are generally a positive signal of alignment, this specific transaction is part of a standard compensation package and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Regeneron Pharmaceuticals, REGN, Insider Transaction, Form 4, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant